Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.
Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
Sevelamer
Decrease in MPA Cmax and AUC0-12h by 30% and 25%, respectively, were observed when
mycophenolate mofetil was concomitantly administered with sevelamer without any clinical
consequences (i.e. graft rejection). It is recommended, however, to administer mycophenolate mofetil
at least one hour before or three hours after sevelamer intake to minimise the impact on the absorption
of MPA. There are no data on mycophenolate mofetil with phosphate binders other than sevelamer.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Sevelamer
Decrease in MPA Cmax and AUC0-12h by 30% and 25%, respectively, were observed when
mycophenolate mofetil was concomitantly administered with sevelamer without any clinical
consequences (i.e. graft rejection). It is recommended, however, to administer mycophenolate mofetil
at least one hour before or three hours after sevelamer intake to minimise the impact on the absorption
of MPA. There are no data on mycophenolate mofetil with phosphate binders other than sevelamer.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Sevelamer
Decrease in MPA Cmax and AUC0-12h by 30% and 25%, respectively, were observed when
mycophenolate mofetil was concomitantly administered with sevelamer without any clinical
consequences (i.e. graft rejection). It is recommended, however, to administer mycophenolate mofetil
at least one hour before or three hours after sevelamer intake to minimise the impact on the absorption
of MPA. There are no data on mycophenolate mofetil with phosphate binders other than sevelamer.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Sevelamer
Decrease in MPA Cmax and AUC0-12h by 30% and 25%, respectively, were observed when
mycophenolate mofetil was concomitantly administered with sevelamer without any clinical
consequences (i.e. graft rejection). It is recommended, however, to administer mycophenolate mofetil
at least one hour before or three hours after sevelamer intake to minimise the impact on the absorption
of MPA. There are no data on mycophenolate mofetil with phosphate binders other than sevelamer.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Version 2026-05-07T14:22:00Z · SHA-256 8464b0a5294445d85b3f9b902633989ca6f57af3990241a80eda4979936ba419 · Passage 79659253a0045e9f636e13fda5c54fdefeeeec59bfa38948c673cdaa82d8d8c0 · Zeichen 6802–7284 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.